JANET GILBREATH: Open Payments
NPI 1013024827 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,906 in 82 payments from 12 companies in 2025. Trend: 2023 $2,080 · 2024 $2,172 · 2025 $1,906
Food & beverage: $1,846Education: $60
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 9 | $370 |
| ABBVIE INC. | 27 | $338 |
| Vanda Pharmaceuticals Inc. | 11 | $310 |
| Teva Pharmaceuticals USA, Inc. | 10 | $247 |
| Otsuka America Pharmaceutical, Inc. | 9 | $205 |
| Axsome Therapeutics, Inc. | 5 | $120 |
| Neurocrine BioSciences, Inc. | 3 | $91 |
| Alkermes, Inc. | 1 | $87 |
| Janssen Pharmaceuticals, Inc | 3 | $73 |
| Corium, LLC | 2 | $29 |
Products named: FANAPT, VRAYLAR, COBENFY, AUSTEDO XR, Auvelity, ABILIFY MAINTENA, INGREZZA, LYBALVI.
Industry payments across ID — which companies pay providers there.
